Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Privium Fund Management B.V.

Privium Fund Management B.V. raised its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 6.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 258,380 shares of the biopharmaceutical company's stock after purchasing an additional 15,868 shares during the quarter. Ultragenyx Pharmaceutical accounts for about 2.5% of Privium Fund Management B.V.'s investment portfolio, making the stock its 10th biggest position. Privium Fund Management B.V. owned about 0.28% of Ultragenyx Pharmaceutical worth $10,870,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Algert Global LLC raised its position in Ultragenyx Pharmaceutical by 46.9% in the third quarter. Algert Global LLC now owns 73,902 shares of the biopharmaceutical company's stock worth $4,105,000 after purchasing an additional 23,580 shares in the last quarter. Bamco Inc. NY bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at approximately $2,666,000. Principal Financial Group Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 740.0% in the 3rd quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company's stock valued at $4,802,000 after purchasing an additional 76,150 shares during the period. Cerity Partners LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $1,773,000. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Ultragenyx Pharmaceutical by 1.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after buying an additional 294 shares during the period. Institutional investors and hedge funds own 97.67% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. HC Wainwright restated a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Piper Sandler dropped their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Monday, March 17th. Wedbush reissued a "neutral" rating and issued a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Cantor Fitzgerald restated an "overweight" rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Finally, Canaccord Genuity Group lifted their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $91.71.

Insider Buying and Selling

In related news, EVP Karah Herdman Parschauer sold 2,990 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the sale, the executive vice president now owns 54,991 shares of the company's stock, valued at approximately $2,358,014.08. The trade was a 5.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Emil D. Kakkis sold 73,434 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $3,091,571.40. Following the completion of the transaction, the chief executive officer now owns 641,731 shares in the company, valued at approximately $27,016,875.10. This trade represents a 10.27 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 136,370 shares of company stock valued at $5,751,499. 5.80% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Price Performance

RARE stock traded up $0.29 during trading hours on Friday, reaching $39.18. The stock had a trading volume of 934,971 shares, compared to its average volume of 776,129. The stock has a 50-day simple moving average of $41.88 and a 200 day simple moving average of $47.45. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $37.02 and a fifty-two week high of $60.37. The stock has a market capitalization of $3.62 billion, a PE ratio of -6.18 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). The business had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.